VYVGART Achieves Primary Endpoint in Phase 3 Myositis Trial for argenx
ARGX sits 48% above its 52-week low of $644.63.
Summary
argenx announced positive Phase 3 topline results for VYVGART Hytrulo in autoimmune myositis, meeting the primary endpoint with a 15.4-point improvement in Total Improvement Score.
Key Events · Product Development and Regulatory · ARGX
-
Phase 3 ALKIVIA Trial Meets Primary Endpoint
Efgartigimod showed a 15.4-point greater improvement in mean Total Improvement Score at Week 52 versus placebo (47.95 vs 32.56, p=0.0011) in the combined IMNM and DM population.
-
First Positive Phase 3 Data in IMNM
In the IMNM subtype, efgartigimod demonstrated a 14.8-point improvement over placebo (p=0.0048), marking the first Phase 3 study to show statistically significant benefit in this refractory disease with no approved therapy.
-
Consistent Efficacy Across Subtypes
DM patients showed a 14.5-point improvement (p=0.1093), not statistically significant in the smaller cohort but clinically meaningful, with all six core set measures favoring efgartigimod.
-
Safety Profile Consistent with Prior Studies
No new safety signals; adverse event rates were comparable to placebo, with injection site reactions more common in the efgartigimod arm (51.2% vs 21.3%).
Analysis · ARGX · Life Sciences
The ALKIVIA trial met its primary endpoint, showing a 15.4-point improvement in Total Improvement Score versus placebo (p=0.0011). This marks the first Phase 3 success in autoimmune myositis, a disease with no approved targeted therapies. The result validates efgartigimod's FcRn mechanism in a new rheumatology indication and supports a regulatory filing. With the stock trading near its 52-week high, this data could expand the market opportunity for VYVGART.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 46% of the 298 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARGX was trading at $955.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.8B. The 52-week trading range was $644.63 to $953.58. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.